
We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser.
CHROME SAFARI FIREFOX
We've detected you are on Internet Explorer. For the best Barrons.com experience, please update to a modern browser. Google Firefox
Barron's
Subscribe Now
Sign In
Barrons
Next:

Share

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/russia-ukraine-war-pharmaceutical-stock-trials-disruption-51646837824

    Healthcare

Russia-Ukraine War Won’t Affect Pharmaceutical Sales, but It Could Disrupt Trials, Companies Say

By
Josh Nathan-Kazis
March 9, 2022 9:59 am ET

    Order Reprints
    Print Article

The global sanctions regime targeting Russia and Belarus hasn’t touched the import of medicines or medical devices, but Western healthcare companies said early this week that the continuing conflict from the Russian invasion of Ukraine could still affect their businesses.

Speaking at investor conferences on Monday and Tuesday, healthcare executives said that the region accounts for only a small proportion of their sales. Some large pharmaceutical companies warned, however, that a large number of clinical trials are run in...
Subscribe or Sign In
to continue reading
Close
Russia-Ukraine War Won’t Affect Pharmaceutical Sales, but It Could Disrupt Trials, Companies Say

The global sanctions regime targeting Russia and Belarus hasn’t touched the import of medicines or medical devices, but Western healthcare companies said early this week that the continuing conflict from the Russian invasion of Ukraine could still affect their businesses.
From
To
Message
SEND

An error has occurred, please try again later.

Thank you

This article has been sent to

Privacy Notice
Cookie Notice
Copyright Policy
Data Policy
Your Ad Choices
Subscriber Agreement & Terms of Use
Barron's Archive
Corporate Subscriptions
Manage Notifications
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved.
Barron's

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.
